Guided Therapeutics, Inc.
GTHP
$0.25
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 178.00K | 118.00K | 1.00K | 7.00K | 38.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.00K | 118.00K | 1.00K | 7.00K | 38.00K |
| Cost of Revenue | 66.00K | 41.00K | 3.00K | 5.00K | 18.00K |
| Gross Profit | 112.00K | 77.00K | -2.00K | 2.00K | 20.00K |
| SG&A Expenses | 1.83M | 1.89M | 1.62M | 1.58M | 867.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.37M | 2.39M | 2.17M | 2.12M | 1.36M |
| Operating Income | -2.20M | -2.27M | -2.16M | -2.11M | -1.32M |
| Income Before Tax | -2.63M | -2.54M | -2.44M | -2.42M | -2.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.63 | -2.54 | -2.44 | -2.42 | -2.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.63M | -2.54M | -2.44M | -2.42M | -2.15M |
| EBIT | -2.20M | -2.27M | -2.16M | -2.11M | -1.32M |
| EBITDA | -2.19M | -2.26M | -2.16M | -2.10M | -1.31M |
| EPS Basic | -0.04 | -0.04 | -0.04 | -0.05 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 290.39M | 265.74M | 242.89M | 229.34M | 220.54M |
| Average Diluted Shares Outstanding | 290.39M | 265.74M | 242.89M | 229.34M | 220.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |